HHS Awards $1.5 Billion Grant to Combat Opioid Addiction
HHS (through SAMHSA) announced a State Opioid Response (SOR) grant funding of nearly $1.5 billion to help address the nation’s opioid addiction and overdose epidemic.
HHS Launches the Inaugural PandemicX 2022 Cohort
HHS has launched the PandemicX 2022 cohort, a program to accelerate private-public collaboration of 15 health tech startups.
NIH Establishes Antiviral Drug Discover Centers
NIH has awarded approximately $577 million to establish nine Antiviral Drug Discovery Centers for Pathogens of Pandemic Concern.
HHS and ED Launch Joint-Department Effort to Expand School-Based Health Services
The U.S. Department of Health and Human Services and U.S. Education Department have launched a joint-department effort to expand school-based health services.
New Test Detects and Measures Biomarkers in Blood Plasma to Earlier Diagnose Alzheimer’s
FDA has granted breakthrough device designation to Roche’s Elecsys Amyloid Plasma Panel, a new solution to enable Alzheimer’s disease to be detected earlier.
High-Dose IVIG Effective in Painful Diabetic Polyneuropathy Resistant to Conventional Treatments
Italian investigators conducted a trial to assess the safety and efficacy of IVIG in treatment-resistant painful diabetic polyneuropathy (DPN).
HHS Expands Funding for Mental Health and Substance Use Services
The Department of Health and Human Services (HHS) through the Substance Abuse and Mental Health Services Administration (SAMHSA) announced two Certified Community Behavioral Health Clinics (CCBHCs) funding opportunities to expand and increase access to evidence-based mental health and substance use services for Americans.
HHS Provides More COVID-19 Relief Funds to Healthcare Providers
The Department of Health and Human Services (HHS) announced more than $413 million in Provider Relief Fund (PRF) payments to more than 3,600 providers across the country.
How the No Surprises Act Protects Consumers
New federal protections shield millions of consumers from surprise medical bills, which are unexpected bills from out-of-network providers, out-of-network facilities or out-of-network air ambulance providers.
Plasma Prekallikrein Inhibition by Antisense Oligonucleotide Reduces Hereditary Angioedema Disease Burden
An investigational antisense oligo-nucleotide (donidalorsen) that acts by degrading plasma prekallikrein messenger RNA was evaluated in patients with hereditary angioedema (HAE) and C1 inhibitor deficiency to assess whether this agent can reduce the frequency of angioedema attacks and the burden of disease.
